BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2009528)

  • 1. Acetylator polymorphism in human colorectal carcinoma.
    Ladero JM; González JF; Benítez J; Vargas E; Fernández MJ; Baki W; Diaz-Rubio M
    Cancer Res; 1991 Apr; 51(8):2098-100. PubMed ID: 2009528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acetylator polymorphism in Alzheimer's disease.
    Ladero JM; Barquero MS; Coria F; Molina JA; Jiménez-Jiménez FJ; Benítez J
    Eur J Med; 1993 May; 2(5):281-3. PubMed ID: 8252158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic acetylator phenotype in bladder cancer patients.
    Ladero JM; Kwok CK; Jara C; Fernandez L; Silmi AM; Tapia D; Uson AC
    Ann Clin Res; 1985; 17(3):96-9. PubMed ID: 4051447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Acetylation polymorphism in lung cancer].
    Laredo Quesada JM; Jara Sánchez C; Benítez Rodríguez J; Fernández Gundín MJ; Vargas Castrillón E; Muñoz González JJ; Llerena Ruiz A; Cobaleda Polo J; Pérez-Manga G
    An Med Interna; 1991 Feb; 8(2):66-8. PubMed ID: 1893005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylator phenotyping in patients with malignant lymphomas, using caffeine as the metabolic probe.
    William BM; Abdel-tawab AM; Hassan EA; Mohamed OF
    Pol J Pharmacol; 2004; 56(4):445-9. PubMed ID: 15520499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetylator phenotype in patients with allergic diseases and its clinical significance.
    Orzechowska-Juzwenko K; Milejski P; Patkowski J; Nittner-Marszalska M; Malolepszy J
    Int J Clin Pharmacol Ther Toxicol; 1990 Oct; 28(10):420-5. PubMed ID: 2258251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetylation phenotype in colorectal carcinoma.
    Ilett KF; David BM; Detchon P; Castleden WM; Kwa R
    Cancer Res; 1987 Mar; 47(5):1466-9. PubMed ID: 3815349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation.
    Oyama T; Kawamoto T; Mizoue T; Yasumoto K; Kodama Y; Mitsudomi T
    Anticancer Res; 1997; 17(1B):577-81. PubMed ID: 9066583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphic N-acetylation of sulfamethazine and benzidine by human liver: implication for cancer risk?
    Peters JH; Gordon GR; Lin E; Green CE; Tyson CA
    Anticancer Res; 1990; 10(1):225-9. PubMed ID: 2334132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arylamine N-acetyltransferase 1 (NAT1) and 2 (NAT2) polymorphisms in susceptibility to bladder cancer: the influence of smoking.
    Okkels H; Sigsgaard T; Wolf H; Autrup H
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):225-31. PubMed ID: 9107426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of the acetylation polymorphism in determining susceptibility of cultured rabbit hepatocytes to DNA damage by aromatic amines.
    McQueen CA; Maslansky CJ; Williams GM
    Cancer Res; 1983 Jul; 43(7):3120-3. PubMed ID: 6850620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Colorectal adenomatous and hyperplastic polyps: smoking and N-acetyltransferase 2 polymorphisms.
    Potter JD; Bigler J; Fosdick L; Bostick RM; Kampman E; Chen C; Louis TA; Grambsch P
    Cancer Epidemiol Biomarkers Prev; 1999 Jan; 8(1):69-75. PubMed ID: 9950242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acetylator phenotype in patients with lung carcinoma--a negative report.
    Burgess EJ; Trafford JA
    Eur J Respir Dis; 1985 Jul; 67(1):17-9. PubMed ID: 4054252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-acetylator phenotypes in hyperthyroidism.
    Siegmund W; Franke G; Meng S; Gothe P; Meng W
    Int J Clin Pharmacol Ther Toxicol; 1988 Aug; 26(8):397-9. PubMed ID: 3220615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
    Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
    Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acetylator phenotype in Iraqi patients with systemic lupus erythematosus.
    Najim RA; Farid YY; Samad TA; Shihab SA
    East Mediterr Health J; 2005; 11(5-6):1003-8. PubMed ID: 16761671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acetylator phenotyping with sulphadimidine in patients receiving isoniazid.
    Ylitalo P; Auterinen L; Marttinen A; Koivula T
    Int J Clin Pharmacol Res; 1984; 4(2):141-4. PubMed ID: 6469440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylator polymorphism in multiple sclerosis.
    Ladero JM; Arroyo R; De Andrés C; Jiménez-Jiménez FJ; Molina JA; Varela de Seijas E; Giménez-Roldán S; Benítez J
    Acta Neurol Scand; 1994 Feb; 89(2):102-4. PubMed ID: 8191871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic acetylator phenotype in diabetes mellitus.
    Ladero JM; Arrojo A; de Salamanca RE; Gomez M; Cano F; Alfonso M
    Ann Clin Res; 1982 Aug; 14(4):187-9. PubMed ID: 7168549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Phenotypes of oxidation and acetylation in Alzheimer's disease--preliminary report].
    Milejski P; Orzechowska-Juzwenko K; Niewiński P; Hurkacz M; Czarnik-Matusewicz H; Leszek J; Rudzik J; Grotthus B
    Psychiatr Pol; 2007; 41(2):261-9. PubMed ID: 17598435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.